Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo

Nicotine and Tobacco Research

Volumn 15, Issue 2, 2013, Pages 567-571

  Buchanan, Taneisha S ^a   Sanderson Cox, Lisa ^b   Thomas, Janet L ^a   Nollen, Nicole L ^b   Berg, Carla J ^c   Mayo, Matthew S ^b   Ahluwalia, Jasjit S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PLACEBO;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TREATMENT DURATION; TREATMENT RESPONSE;

BUPROPION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84872844619     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nts143     Document Type: Article

References (17)

1. Ahluwalia, J. S., Okuyemi, K., Nollen, N., Choi, W. S., Kaur, H., Pulvers, K., et al. (2006). The effects of nicotine gum and counseling among African American light smokers: A 2 × 2 factorial design. Addiction, 101, 883 - 891. doi:10.1111/j. 13600443.2006.01461.
2. Cox, L. S., Faseru, B., Mayo, M. S., Krebill, R., Snow, T. S., Bronars, C. A., et al. (2011). Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. Trials, 12, 22. doi:10.1186/174562151222.
3. Cox, L. S., Nollen, N. L., Mayo, M. S., Choi, W. S., Faseru, B., Benowitz, N. L., et al. (2012). Bupropion for smoking cessation in African American light smokers: A randomized controlled trial. Journal of the National Cancer Institute, 104, 290 - 298. doi:10.1093/jnci/djr513.
4. Fagan, P., & Rigotti, N. A. (2009). Light and intermittent smoking: The road less traveled. Nicotine & Tobacco Research, 11, 107 - 110. doi:10.1093/ntr/ntn015.
5. Gariti, P., Lynch, K., Alterman, A., Kampman, K., Xie, H., & Varillo, K. (2009). Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. Journal of Substance Abuse Treatment, 37, 247-255. doi:10.1016/j.jsat.2009. 01.006.
6. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström test for nicotine dependence: A revision of the Fagerström tolerance questionnaire. British Journal of Addiction, 86, 1119-1127. doi:10.1111/j.1360-0443.1991.tb01879.x.
7. Hughes, J. R., & Krahn, D. (1985). Blindness and the validity of the double-blind procedure. Journal of Clinical Psychopharmacology, 5, 138-142. doi:10.1097/00004714-198506000-00003.
8. Lerman, C., Roth, D., Kaufmann, V., Audrain, J., Hawk, L., Liu, A., et al. (2002). Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug and Alcohol Dependence, 67, 219-223. doi:10.1016/S0376-8716(02)00067-4.
9. McCarthy, D. E., Piasecki, T. M., Lawrence, D. L., Jorenby, D. E., Shiffman, S., & Baker, T. B. (2008). Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction, 103, 1521-1533. doi:10.1111/j.1360-0443. 2008.02275.x.
10. Mooney, M., White, T., & Hatsukami, D. (2004). The blind spot in the nicotine replacement therapy literature: Assessment of the double-blind in clinical trials. Addictive Behaviors, 29, 673-684. doi:10.1016/j.addbeh.2004.02.010.
11. Nollen, N. L., Mayo, M., Ahluwalia, J. S., Tyndale, R. F., Benowitz, N. L., Faseru, B., et al. (2012). Factors associated with discontinuation of bupropion and counseling session attendance among African American lights smokers in a randomized clinical trial. Manuscript submitted for publication.
12. Oken, B. S. (2008). Placebo effects: Clinical aspects and neurobiology. Brain: A Journal of Neurology, 131, 2812-2823. doi:10.1093/brain/awn116.
13. Okuyemi, K. S., Ahluwalia, J. S., Banks, R., Harris, K. J., Mosier, M. C., Nazir, N., et al. (2004). Differences in smoking and quitting experiences by levels of smoking among African Americans. Ethnicity & Disease, 14, 127-133.
14. Price, D. D., Finniss, D. G., & Benedetti, F. (2008). A comprehensive review of the placebo effect: Recent advances and current thought. Annual Review of Psychology, 59, 565-590. doi:10.1146/annurev.psych.59.113006.095941.
15. Schnoll, R. A., Epstein, L., Audrain, J., Niaura, R., Hawk, L., Shields, P. G., et al. (2008). Can the blind see? participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. Journal of Substance Abuse Treatment, 34, 234-241. doi:10.1016/j. jsat.2007.04.004.
16. Shiffman, S. (2005). Nicotine lozenge efficacy in light smokers. Drug and Alcohol Dependence, 77, 311-314. doi:10.1016/j. drugalcdep.2004.08.026.
17. Thomas, J. L., Guo, H., Lynam, I. M., Powell, J. N., Okuyemi, K. S., Bronars, C. A., et al. (2008). The impact of perceived treatment assignment on smoking cessation outcomes among African American smokers. Journal of General Internal Medicine, 23, 1361-1366. doi:10.1007/s11606-008-0656-3.